louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06434675: Prevalence of Variants of Nasal Cavity and Nasal Septum in Nepalese
Official title: Anatomical Variants of Nasal Cavities and Nasal Septum in Nepalese Patients: A Retrospective Cross-Sectional Study at a Tertiary Care Center
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Nasal Septum; Deviation, Congenital
Keywords: Nasal Septum
Nasal Cavity
Turbinate
Lead sponsor: Grande International Hospital, Nepal
Sponsor class: OTHER
First posted: 2024-05-30
Enrollment: 343
Sex: ALL
Minimum age (years): 13
Maximum age (years): 91
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Patient of age 13 years and more undergoing NCCT PNS and Head for chronic rhinosinusitis , headache and vertigo

Brief summary: A retrospective study was conducted on 343 patients. CT PNS and head of the patients were evaluated for variants of nasal septum and nasal cavity.

Detailed description: A retrospective study was conducted on 343 patients aged 13 years and above. Two investigators, each with 3 to 4 years of experience in the field of radiology, evaluated computed tomography scans of the paranasal sinuses and the head of these patients. The nasal septum was evaluated for degree and types of variants. Various variants of nasal cavities and nasal septum were also evaluated.

Eligibility criteria: Inclusion Criteria:

1)Patients undergoing NCCT PNS and Head for chronic rhinosinusitis, headache and vertigo

Exclusion Criteria:

1. Patient less than 13 years age
2. Patients with recent trauma
3. Patient with large mass/ extensive polyposis

Primary outcomes:
measure: Prevalence of variants of Nasal septum
timeFrame: 6 months
measure: Prevalence of variants of nasal cavity
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Kathmandu
country: Nepal
facility: Prajwal Dahal
state: Bagmati
Study officials:
affiliation: Grande International Hospital
name: PRAJWAL DAHAL
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06031675: Mechanism for Exercise to Delay Cardiac Aging
Official title: The αKlotho Protein-mediated NLRP3/Caspase-1/GSDMD Pathway Counteracts Myocardial Stunning: a Novel Mechanism for Exercise to Delay Cardiac Aging
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Activity, Motor
Health Behavior
Keywords: vigorous intermittent lifestyle physical activity
wearable device
isokinetic performance
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2023-09-11
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: University students

Brief summary: The goal of this clinicaltrial is to assess and compare isokinetic performance, surface electromyography, laboratory parameters, and cardiorespiratory function both before and after engaging in vigorous intermittent lifestyle physical activity(VILPA) within a healthy population.

The main question it aims to answer is:

\[1\] Does VILPA yield effective outcomes?

Throughout the course of the trial, participants will engage in a simulated regimen of vigorous intermittent lifestyle physical activity for a duration of 8 weeks. The efficacy of the exercise protocol will be quantified and evaluated through the utilization of a wearable device.


Eligibility criteria: Inclusion Criteria:

1. Healthy Adults
2. No exercise habits (more than 3 months)

Exclusion Criteria:

1. Exercising ≥ 3 times per week;
2. the presence of chronic diseases, such as hypertension, hyperglycemic states, etc;
3. have conducted an exercise program in the past three months.

Primary outcomes:
measure: Isometric Strength Test
timeFrame: 15 minutes
measure: Surface electromyography
timeFrame: 30 minutes
measure: Exercise Flat Test
timeFrame: 30 minutes
Secondary outcomes:
measure: Fasting glucose
timeFrame: 5 minutes
measure: Blood lipid
timeFrame: 5 minutes
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Guangdong Pharmaceutical University
state: Guangdong
Study officials:
affiliation: Department of Health, Guangdong Pharmaceutical University
name: Lizhen Liao, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05798975: Analysis of Heart Rate Variability After a Physical Exercise Session
Official title: Analysis of Heart Rate Variability After One Session of Aerobic or Resistance Physical Exercise in Controlled Hypertensive Individuals: Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypertension
Lead sponsor: Instituto de Cardiologia do Rio Grande do Sul
Sponsor class: OTHER
First posted: 2023-04-05
Enrollment: 36
Sex: ALL
Minimum age (years): 30
Maximum age (years): 59
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: AE= Aerobic Exercise RE= Resistance Exercise CT= Control (no exercise)
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Systemic arterial hypertension (SAH) is a multifactorial clinical condition, characterized by sustained elevation of blood pressure levels, contributing to 50% of deaths from cardiovascular disease. The Autonomic Nervous System (ANS) plays a fundamental role in the regulation of Blood Pressure (BP) and is closely associated with Heart Rate (HR). HR changes are called Heart Rate Variability (HRV). In individuals with SAH, HRV indices are reduced compared to normotensive individuals, showing changes in autonomic modulation, thus increasing the risk for cardiovascular events. The objective of this study will be to analyze the Heart Rate Variability in individuals with controlled SAH after a session of aerobic (EA) or resistance (RE) physical exercise.

Detailed description: Controlled hypertensive individuals aged between 30 and 59 years will be selected, for convenience, who use the services of the Instituto de Cardiologia do Rio Grande do Sul. Volunteers will be randomly assigned to an EA session (40 minutes on cycle ergometer, 60% of heart rate reserve) or RE (2 exercises for lower limbs and 2 for upper limbs with 4 sets of 12 repetitions at 60% 1-RM) or control group without exercise. HRV data will be collected by ECG (Wincardio USB - Version 11.1.0.0, MICROMED Biotecnologia Ltda, Brasília - DF - Brazil) during 10 minutes before the exercise session, 10 minutes after the exercise session, 1h and 2h post-session . It is expected to estimate results that may demonstrate clarifications about the impact of a physical exercise session on HRV in controlled hypertensive individuals.

Eligibility criteria: Inclusion Criteria:

* Controlled Systemic Alterial Hypertension

Exclusion Criteria:

* Diabetes mellitus;
* heart failure;
* coronary artery disease;
* chronic renal failure;
* body mass index (BMI) ≥ 35 kg/m2;
* smokers;
* individuals with injuries to the upper and lower limbs that make the exercise protocol impossible;
* not using antihypertensive medication and using beta-blocker and/or alpha-blocker medication.

Primary outcomes:
measure: Heart Rate Variability.
timeFrame: 4 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Porto Alegre
country: Brazil
facility: Diego Silveira da Silva
state: RS
Study officials:
References:
Clinical trial NCT03782675: Air Barrier System for the Reduction of Airborne Colony-forming Units During Total Shoulder Arthroplasty
Official title: Air Barrier System for the Reduction of Airborne Particulate and Colony-forming Units (CFU) During Total Shoulder Arthroplasty.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Osteo Arthritis Shoulders
Keywords: Total shoulder replacement
operating room air
surgical site infection
airborne CFU
Lead sponsor: Nimbic Systems, LLC
Sponsor class: INDUSTRY
Collaborators: name: Texas Orthopedic Hospital
First posted: 2018-12-20
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The objective of this study is to determine whether the Air Barrier System device reduces airborne colony-forming units (e.g., bacteria) present at a surgery site during total shoulder arthroplasty surgeries.

Detailed description: The Air Barrier System (ABS) is a device that uses localized clean air flow to shield a surgery site from ambient airborne contamination. This study examines the hypothesis that the ABS can reduce the presence of airborne CFU and particles at the surgery site during total arthroplasty surgery.

Eligibility criteria: Inclusion Criteria:

* Candidate for total shoulder arthroplasty

Exclusion Criteria:

* Prior history of infection
* Revision surgery
* Screens positive for MRSA

Primary outcomes:
measure: CFU counts
timeFrame: Four months
measure: Particle counts
timeFrame: Four months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Texas Orthopedic Hospital
name: Gregory Stocks, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Stocks GW, Self SD, Thompson B, Adame XA, O'Connor DP. Predicting bacterial populations based on airborne particulates: a study performed in nonlaminar flow operating rooms during joint arthroplasty surgery. Am J Infect Control. 2010 Apr;38(3):199-204. doi: 10.1016/j.ajic.2009.07.006. Epub 2009 Nov 12.
Clinical trial NCT01494675: Procalcitonin as a Tool to Shorten Antibiotic Therapy in the ICU
Official title: Clinical Impact of Procalcitonin to Shorten Antimicrobial Therapy in Septic Patients With Proven Bacterial Infection in an Intensive Care Setting
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sepsis
Keywords: procalcitonin
duration of the antibiotic therapy
sepsis
Lead sponsor: Hospital Israelita Albert Einstein
Sponsor class: OTHER
First posted: 2011-12-19
Enrollment: 81
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Intervention model: PARALLEL

Brief summary: Recently, biomarkers like procalcitonin have been studied in order to help physicians to decrease the duration of the antibiotic therapy. The investigators objective was to assess whether the decrease in procalcitonin levels could be used to reduce the antibiotic therapy in critically ill patients with a proven infection without risking a worse outcome.


Eligibility criteria: Inclusion Criteria:

* all patients admitted in the intensive care unit with sepsis, severe sepsis and septic shock with a microbiologically confirmed infection (blood, urine, tracheal aspirate or bronchoalveolar fluid culture)

Exclusion Criteria:

* onset of the antibiotic therapy more than 48 hours before the date when the cultures were performed
* patients less than 18 years old
* known pregnancy
* infections requiring prolonged antibotic therapy such as endocarditis, hepatic or brain abscess, deep abscess, mediastinitis and osteomyelitis
* severe infection caused by virus, parasites, fungi or chronic prostatitis
* negative cultures in patients with suspected sepsis, severe sepsis or septic shock

Primary outcomes:
measure: reducing the duration of antibiotic therapy
timeFrame: 2 years
Secondary outcomes:
measure: all cause mortality
timeFrame: 2 years
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Hospital Israelita Albert Einstein
state: Sâo Paulo
Study officials:
affiliation: Hospital Israelita Albert Einstein
name: Rodrigo O Deliberato, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02407275: Rhinosinusites Chroniques
Official title: ETUDE DU MICROBIOTE DES RHINOSINUSITES CHRONIQUES DIFFICILES A TRAITER PAR METAGENOMIQUE ET CULTUROMIQUE
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sinusitis
Chronic Disease
Refractory
Lead sponsor: Institut Hospitalo-Universitaire Méditerranée Infection
Sponsor class: OTHER
Collaborators: name: University Hospital, Marseille
First posted: 2015-04-02
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: To analyse and describe sinus microbiota, during hard to treat (or refractory) rhinosinusitis, using culturomic and metagenomic methods (i.e. to culture on many different medium of culture to grow hard to cultivate bacteria + to sequence and analyse all DNA contained in samples).

Samples are middle meatus swabs or pus aspiration, done during usually patient following.


Eligibility criteria: Inclusion Criteria:

* \>18 year old
* chronic refractory rhinosinusitis
* to require middle meatus swab or other sinus sample
* absence of opposition

Exclusion Criteria:

* \<18 year old
* pregnant women
* breastfeeding
* under trusteeship
* under guardianship

Primary outcomes:
measure: Sinusian microbiota description
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Marseille
country: France
facility: Service ORL et de Chirurgie Cervico - Faciale/ AP-HM
Study officials:
affiliation: IHU Méditerranée Infection
name: Pierre-Edouard Fournier, Professor
role: STUDY_CHAIR
References:
Clinical trial NCT04366375: Pentraxin-3 in Hysterectomy Patients
Official title: Comparison of the Tissue Trauma Markers Following Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Laparoscopic Hysterectomy
Abdominal Hysterectomy
Keywords: Pentraxin-3
tissue trauma
hysterectomy
neutrophil to lymphocyte ratio
Lead sponsor: Muğla Sıtkı Koçman University
Sponsor class: OTHER
First posted: 2020-04-28
Enrollment: 40
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A total of 40 patients, composed of 20 TLH+BSO patients and 20 TAH+BSO patients were included into the study.

Brief summary: Comparison of the Tissue Trauma Markers Following Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy

Detailed description: Acute trauma and major surgeries activate a series of cascades to evoke systemic inflammatory response. The magnitude of the resulting inflammatory response is proportional to the severity of the tissue trauma. Abdominal or laparoscopic technique is widely used for the purpose of hysterectomy surgery. It is crucial for many aspects to compare these two techniques of hysterectomy in terms of the surgery-induced trauma.

In this study, the severity of the inflammatory response resulting from the tissue trauma due to the techniques of TLH+BSO and TAH+BSO applied in our department were compared based on the PTX-3 molecule.

Eligibility criteria: Inclusion Criteria:

·TLH+BSO patients and TAH+BSO patients

Exclusion Criteria:

* History of a chronic disease (coronary artery disease, diabetes mellitus, hypertension, coronary liver failures, chronic kidney disease, chronic respiratory diseases, connective tissue disorders) which may affect levels of PTX-3 and other inflammatory markers.
* Prior surgery due to malignancy.
* History of an intra-abdominal surgery, except for cesarean section.
* History of any disease which may lead to intra-abdominal adhesions (endometriosis, past pelvic infection).

Primary outcomes:
measure: Pentraxin-3 level
timeFrame: Before 24 hours preoperatively and upto 24 hours postoperatively
Secondary outcomes:
measure: (NLR)
timeFrame: Up to 24 hours postoperative
Other outcomes:
Locations:
Study officials:
affiliation: Mugla Sıtkı Kocman University Faculty of Medicine
name: Burak SEZGİN, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03304275: The Feasibility of Pertussis Immunization in a Canadian Emergency Department
Official title: The Feasibility of Pertussis Immunization in a Canadian Emergency Department
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pertussis
Keywords: Pertussis
Vaccination
Emergency Department
Lead sponsor: University of Prince Edward Island
Sponsor class: OTHER
Collaborators: name: The Queen Elizabeth Hospital
First posted: 2017-10-06
Enrollment: 644
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Randomized controlled trial of 2 strategies to provide adults with the Tdap vaccine to patients presenting to the emergency department. Rates of vaccination as well as effects on department efficiency will be measured.

Detailed description: This study is a prospective randomized, controlled trial of two strategies to provide patients with the pertussis vaccine. Eligible adult patients with be offered pertussis vaccination in the Emergency Department vs. a referral to Public Health for pertussis vaccination. The effect of both strategies on triage time as well as measure of emergency department efficiency including length of stay, time to physician and left without being seen rates will be compared. At a four-month follow up, rates of pertussis vaccination will be measured.

Eligibility criteria: Inclusion Criteria:

* Adults age 18 and above
* Have not received Tdap vaccine as an adult (age 18 and above) or have not received Tdap vaccine within 10 years, or unsure of vaccination status

Exclusion Criteria:

* Acute significant illness (Canadian Triage and Acuity Scale = 1)
* Deemed "in too much distress" by triage nurse
* Acute Febrile illness
* Allergy to vaccine or vaccine components
* Pts presenting for wound care (are normally given the vaccine as part of wound care)
* Pregnancy \< 26 weeks

Primary outcomes:
measure: Rate of immunization
timeFrame: One day
Secondary outcomes:
measure: Length of Stay
timeFrame: One day
measure: Left with out being seen rate
timeFrame: One day
measure: Time to physician
timeFrame: One day
measure: Patient refusals
timeFrame: One day
measure: Nursing satisfaction
timeFrame: One day
measure: Additional vaccine received
timeFrame: One day
measure: Triage time
timeFrame: One day
Other outcomes:
Locations:
city: Charlottetown
country: Canada
facility: Queen Elizabeth Hospital
state: Prince Edward Island
Study officials:
affiliation: University of Prince Edward Island
name: Aaron Sibley, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02083575: Role of Vitamin C to Augment Iron Chelation With DFP or DFX
Official title: Study of Safty and Efficacy of Adjuvant Vitamin c in Augmenting Iron Chelation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Vitamin c
Thalassemia Major
Iron Chelation
Keywords: vitamin c
thalassemia major
iron chelation
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2014-03-11
Enrollment: 50
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: role of Vit C to Augment iron chelation with DFP or DFX in thalassemic patients.

Detailed description: assess safety and efficacy of Vit C to Augment iron chelation with DFP or DFX in thalassemic patients.

Eligibility criteria: Inclusion Criteria:

* • Subjects with overload secondary to thalassemia major

Exclusion Criteria:

* • with HIV positive or have active HCV.

  * A history of serious immunologic hypersensitivity to any medication such as anaphylaxis or angioedema.
  * Participation in a previous investigational drug study within the 30 days preceding screening.
  * A woman of childbearing potential must have a negative serum pregnancy test at screening. She must use a medically acceptable form of birth control during the study and for a month afterwards who are pregnant or breast-feeding.
  * An inability to adhere to the designated procedures and restrictions of this protocol.

Primary outcomes:
measure: Vit C to Augment iron chelation
timeFrame: 12 months
measure: vitamin c augmenting effect of iron chelator
timeFrame: 12 month
Secondary outcomes:
measure: adverse related events
timeFrame: 12 month
Other outcomes:
Locations:
city: Cairo,
country: Egypt
facility: Pediatric Hematology clinic, Ain Shams University Egypt
Study officials:
affiliation: Ain Shams University
name: MOHSEN S ELALFY, PROF.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04992975: Brain Iron Toxicity and Neurodegeneration - A 7T MRI Study
Official title: Brain Iron Toxicity and Neurodegeneration - An Ultrahigh Field (7T) MRI Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Prodromal Alzheimer's Disease
Mild Cognitive Impairment
Keywords: Ultrahigh Field MRI
7T MRI
QSM
Lead sponsor: Nottingham University Hospitals NHS Trust
Sponsor class: OTHER
First posted: 2021-08-06
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Alzheimer's Group: Preclinical or Prodromal Alzheimer's disease classified as either A+T-N- or A+T+N- Control Group: individual within 1.5 standard deviation of normal cognition in all tests

Brief summary: A longitudinal observational neuroimaging study of individuals with Early Onset Alzheimer's disease during the prodromal phase, and matched control group - Ultrahigh Field MRI study at 7T

Detailed description: This study aims to determine whether high resolution MRI at 7T and Quantitative Susceptibility Mapping (QSM) can demonstrate a specific pattern of iron overload in strategically important areas of brain as a sensitive marker of pathological Alzheimer's disease i.e. patients with subjective or mild cognitive impairment associated with Amyloid or tau pathological state in the cerebrospinal fluid.

Eligibility criteria: Inclusion Criteria:

* Ability to provide informed consent
* Patients with pathological diagnosis of Alzheimer's disease according to the National Institute on Aging and Alzheimer's Association, NIA-AA, criteria (Alzheimer's group) or cognitively normal individuals within 1.5 standard deviation of normal in all tests (control group)

Exclusion Criteria:

* Lack of mental capacity to consent to study involvement
* Not speaking English before age 5 years
* Learning disability
* Schizophrenia
* Substance misuse
* Implanted devices not certified as compatible with ultra-high field MRI (e.g. cardiac pacemaker)
* Pregnancy

Primary outcomes:
measure: Quantitative Susceptibility Mapping, QSM (from 7T MRI data) to hippocampal subfield volume loss at 1 year
timeFrame: one year
Secondary outcomes:
measure: cross-sectional and longitudinal changes in QSM in the hippocampal subfields
timeFrame: one year
measure: neuropsychological measures in relation to QSM and volume loss in hippocampal subfields
timeFrame: one year
Other outcomes:
Locations:
city: Nottingham
country: United Kingdom
facility: Nottingham University Hospitals NHS Trust
state: East Midland
Study officials:
affiliation: Nottingham University Hospitals NHS Trust
name: Akram Hosseini
role: PRINCIPAL_INVESTIGATOR
References: